60 results about "Cholesterol synthesis" patented technology

This invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and/or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway including interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and inhibition of the signal transduction pathway.

Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans.

The present invention provides pharmaceutical compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, hypercholesterolemia, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, cholesterol gallstones, and lipid storage diseases. The compositions, methods, combinations, and kits of the present invention are pharmaceutical compositions comprising atherapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, and compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate. A typical pharmaceutical composition of the invention contains and effective amount of atorvastatin and an effective amount of policosanol.

The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption.

The subject invention pertains to materials and methods for treating oncological disorders. The subject invention also pertains to materials and methods for preventing or reducing the development by cancer cells of resistance to an anticancer therapy, such as chemotherapy, radiotherapy and/or immunotherapy. In one embodiment, a patient is treated with an agent that inhibits cholesterol synthesis or that prevents or reduces the increase in cholesterol synthesis observed in therapy-resistant cancer cells. In another embodiment, a patient is treated with an agent that increases the expression, activity, or amount of a Bim protein in a cell. In another embodiment, a patient is treated with an agent to inhibit or reduce cancer cell adhesion to extracellular matrices or stromal cells. In another embodiment, a patient is treated with an agent to inhibit expression of a gene of function of a protein of the FANC/BRCA pathway. In a further embodiment, a patient is treated with an agent to prevent or reduce the DNA crosslink repair function of a cell.

The invention relates to the preparation of a wild cactus polyoses extract and the highly effective function thereof for reducing serum cholesterase. The extract is a polyoses extracted from the natural wild cactus polyoses, and can reduce the total cholesterol content in the hypercholesterolemia and obviously improve the lipid metabolic disturbance by improving the activity of in vivo lipid metabolic key enzyme lecithin cholesterin acylase and reducing the activity of synthetical rate-limiting enzyme 3-hydroxy-3-methyl pentane diacid coenzyme A reductase of liver cholesterin; the invention has no obviouse adverse reaction and can be used for preparing medicines used for lowering the cholesterin.

The invention relates to a streptococcus faecium function signal molecule preparation, a streptococcus faecium bacteria strain is carried out the anaerobic fermentation at 35 to 38 DEG C and the centrifugal concentration to obtain a concentrate of streptococcus faecium bacteria, the bacterial cell wall is broken by high pressure, and the freeze-drying is carried out to obtain the preparation raw powder containing the streptococcus faecium function signal molecules. As the streptococcus faecium function signal molecules can be combined with a specific receptor at the intestinal epithelial cells, the issued signal can induce the excessive cholesterol in the body to carry out the transformation, control the activity of the cholesterol synthase, reduce the excessive cholesterol generated or absorbed in the human body, and effectively control the obesity. The streptococcus faecium function signal molecule preparation is simultaneously matched with a bifidobacterium function signal molecule preparation, a lactobacillus function signal molecule preparation and a bacteroides function signal molecule preparation to be prepared into a series of products containing various probiotics function signal molecules for lipid-lowering and weight-losing, thus fundamentally reducing the risks of coronary heart disease, atherosclerosis, heart diseases, angina, myocardial infarction, obesity and other diseases during the process of being eaten by the people.

This invention relates to oxysteroids and oxysteroid hormones which have been identified. These oxysteroids are C27 modified sterols, particularly derivatives of intermediates in cholesterol synthesis, including lanosterol, zymosterol and desmosterol, including C27 diol and C27 acid derivatives, as well as related compounds and analogs thereof. The oxysteroids are capable of binding to or otherwise interacting with orphan nuclear receptors to result in modulation of gene expression. The invention further relates to methods of modulating the rate of cholesterol synthesis in a mammal. More specifically, the invention relates to treatment of cholesterol-related conditions which are improved or ameliorated by modulating the rate of cholesterol synthesis or cholesterol metabolism in a human in need thereof by administration of these oxysteroids, analogs or antagonists thereof. The invention includes methods for ameliorating, treating or preventing macular degeneration in a mammal comprising administering to said mammal an agent which stimulates or enhances the expression or activity of steroid sulphotransferase (SLUT2), particularly SLUT2B1b, or which stimulates or enhances the expression or activity of CYP27A1 or sterol 27-hydroxylase or otherwise increasing the sulfonation or 27-hydroxylation of cholesterol intermediates, including 7-ketocholesterol. Assays for identification of analogs, antagonists or modulators of these oxysteroids or of sterol 27-hydroxylase are also provided.

The invention discloses a traditional Chinese drug for lowering lipid, improving effects and attenuating functions of statins drugs, which is prepared by raw materials according to the proportions as follows: 1000 portions to 3000 portions of star anise powder, 500 portions to 1000 portions of Seleniotatin red yeast rice and 0.01 portions to 0.05 portions of beta-cyclodextrin inclusion selenium. By the comprehensive action of active ingredients extracted from the star anise powder and Seleniotatin red yeast rice, and the beta-cyclodextrin inclusion selenium, the traditional Chinese drug has the lipid management function for controlling cholesterol synthesis, the function for healing and maintaining blood vessel endothelium so as to ensure youthful blood vessel as well as liver protection, spleen strengthening and stomach nourishing, the functions of eliminating free radicals and enhancing the immune function of organism and the like; the traditional Chinese drug has the functions of improving the functions of and attenuating the statins drugs and can solves the fundamental problems of the origins of cardiovascular and cerebrovascular diseases from many aspects without toxic and side effects, therefore the traditional Chinese drug can be used in a comparatively large dose for a comparatively long time, and a new choice is provided for the treatment of hyperlipemia and cardiovascular and cerebrovascular diseases caused by hyperlipemia and atherosclerosis as well as the control of the occurrence of cardiovascular and cerebrovascular events.

The invention discloses solid granules capable of lowering blood fat and relaxing bowels and a preparation method of the solid granules. The preparation method comprises the following steps: grinding yellow beans, expanding, adding glucose, NaCl, dried orange peel, red jujubes, artichoke, endives, flaxseeds, bacillus natto, bacillus lacticus, lactobacillus plantarum, lactobacillus rhamnosus and milk powder, performing liquid fermentation twice, concentrating and drying. The solid granules are capable of dissolving thrombi caused by platelet aggregation, reducing lipid thrombi and blood viscosity caused by cholesterol crystal and lipid plaque adhesion, improving blood circulation and intestinal microecological environment and effectively preventing and treating gastrointestinal diseases such as constipation. Meanwhile, the solid granules are also capable of promoting cholesterol excretion, inhibiting endogenous cholesterol synthesis, reducing the content of triglyceride, low-density lipoprotein and very-low-density lipoprotein and increasing the content of high-density serum lipoprotein so as to improve serum lipid, reduce capillary fragility caused by hyperlipidemia and arteriosclerosis, and protect heart and cerebral vessels.

The invention relates to Chinese wolfberry vinegar rich in Monacolin K and gamma-aminobutyric acid and a preparation method thereof. The Chinese wolfberry vinegar is prepared by the following steps of: preparing germinated rice by using glutinous rice, boiling and gelatinizing the germinated rice, cooling the obtained paste, inoculating the cooled paste with lactic acid bacteria and monascus, performing acidifying, liquefying and saccharifying at the same time to obtain saccharified mash, adding water into Chinese wolfberry fruits, performing pulping, mixing Chinese wolfberry pulp with the saccharified mash, inoculating the obtained mixture with saccharomyces cerevisiae, carrying out alcoholic fermentation, inoculating the fermented material with acetic acid bacteria, and carrying out liquid deep ventilation fermentation. In the germination process of the glutinous rice, the content of gamma-aminobutyric acid is remarkably increased, and the aminobutyric acid has the activities of reducing blood pressure, calming the mind, improving kidney function and liver function, promoting long-term memory, promoting growth hormone secretion and the like. The germinated rice is fermented by the functional monascus, so that a large amount of lovastatin substances can be generated and have the functions of blocking cholesterol synthesis and regulating blood fat. In addition, the Chinese wolfberry fruits are rich in lycium barbarum polysaccharides, polyphenols and flavonoids, and have a good antioxidant effect. The Chinese wolfberry vinegar is red and bright in color, refreshing in taste,outstanding in ester fragrance and mellow in sour feeling.

The invention discloses a cholic acid derivative represented by the formula (I) and a preparation method thereof. The target product cholic acid derivative is prepared by esterification, oxidation, bromination, debromination, 4,4-dimethylation, C-7 oxidation, reduction, TBSCl protection, iodation, cyano substitution, Wittig, Grignard, TBS-removing protection and other reactions. The invention alsoprovides an application of the cholic acid derivative in inhibiting cholesterol synthesis and reducing cholesterol and triglyceride levels in a body; the cholic acid derivative can be used for preparing drugs for preventing and treating hypercholesterolemia, hypertriglyceride, atherosclerosis and other diseases, and has good application prospects.

The present invention relates to a novel methyl analog of simvastatin, which has the ability to inhibit the synthesis of cholesterol. The compound of the present invention holds promise for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders. The invention also relates to a process for making the novel compound.

Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate myocardial function in a mammal involving administering to the mammal (a) a compound that includes eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with dietary restrictions (resulting in aggressive loading of marine lipids), whereby a serum LDL concentration of less than 75 mg/dl (and preferably less than 55 mg/dl) is achieved. One particular method involves administering to the mammal a combination that includes (a) a compound that includes an eicosapentaeneoic or docosahexaeneoic acid (for example, a marine lipid) and (b) a cholesterol synthesis or transfer inhibitor, and which may also optionally include aspirin and/or niacin. The methods and compositions of the invention may also further include a bile acid sequestrant and/or buspirone. Also disclosed are methods for treating heart disease that involve administration of buspirone.

The invention discloses an application of a chinaroot greenbrier alcohol extract to preparation of a weight and fat reducing medicine. The chinaroot greenbrier alcohol extract can suppress cholesterol synthesis, promote fat oxygenolysis, decrease the lipid content of serum and livers, finally suppress fat deposition in an abdominal cavity and reduce increase of the body weight of mice by adjusting expression of lipid metabolism related genes and protein in high fat diet-induced obese mouse livers and fat tissues and adjusting activity of lipolysis related enzyme in the livers. The weight and fat reducing medicine is clear in target, small in side effect and high in clinical effective rate.

The invention discloses tea seed meal used as a squalene synthetase inhibitor and application of the tea seed meal in reduction of lipid. It is found that the tea seed meal made of small fruits of camellia is an effectively inhibitor for a squalene synthetase. The squalene synthetase is an important enzyme for synthesis and metabolism of cholesterol and can catalyze two molecules of farnesyl diphosphate to produce squalene diphosphate serving as an intermediate under the action of reductive dimerization. Under the action of NADPH reduction, squalene diphosphate produces squalene, and squaleneis further synthesized into cholesterol. The cholesterol level can be lowered by inhibiting the activity of the squalene synthetase. Moreover, it is reported that the squalene synthetase inhibitor canlower not only the cholesterol level but also the triglyceride level, so that a lipid lowering effect is achieved. Therefore, the tea seed meal made of small fruits of camellia can achieve the lipidlowering effect by inhibiting the squalene synthetase and can be prepared into food, medicine or health care products for lowering lipid.

The invention belongs to the field of biomedicine and relates to use of FBP aldolase in preparation of AMPK activating drugs. The present invention also relates to use of the FBP aldolase in preparation of drugs for inhibiting cholesterol synthesis, drugs for reducing fatty acid synthesis, drugs for preventing and/or treating diabetes, drugs for preventing and/or treating tumors, drugs for preventing and/or treating Parkinson's disease, drugs for preventing and/or treating Alzheimer's disease or drugs for prolonging the lifespan of organisms. The FBP aldolase is used as a target to develop theAMPK activating drugs. Difficulties existing in the prior art in direct using of AMPK as a drug target can be overcome, and the FBP aldolase has a good application prospect.